Filtered By:
Condition: Heart Disease
Education: Study
Procedure: Heart Transplant
This page shows you your search results in order of date.
Order by Relevance | Date
Total 109 results found since Jan 2013.
Can ‘toxic’ bilirubin treat a variety of illnesses?
Generations of medical and biology students have been instilled with a dim view of bilirubin. Spawned when the body trashes old red blood cells, the molecule is harmful refuse and a sign of illness. High blood levels cause jaundice, which turns the eyes and skin yellow and can signal liver trouble. Newborns can’t process the compound, and although high levels normally subside, a persistent surplus can cause brain damage.
Yet later this year up to 40 healthy Australian volunteers may begin receiving infusions of the supposedly good-for-nothing molecule. They will be participating in a phase 1 safety trial, sponsored ...
Source: ScienceNOW - June 8, 2023 Category: Science Source Type: news
Risk of hospital admission or emergency department presentation due to diabetes complications: a retrospective cohort study in Tasmania, Australia
ConclusionsOur results demonstrated the high demand on hospital services due to diabetes complications (especially macrovascular complications) and highlighted the importance of preventing and properly managing microvascular complications. These findings will support future resource allocation to reduce the increasing burden of diabetes in Australia.PMID:37137728 | DOI:10.1071/AH22271
Source: Australian Health Review - May 3, 2023 Category: Hospital Management Authors: Ngan T T Dinh Barbara de Graaff Julie A Campbell Matthew D Jose John Burgess Timothy Saunder Alex Kitsos Petr Otahal Andrew J Palmer Source Type: research
Diagnosis of Coronary Artery Disease based on Machine Learning algorithms Support Vector Machine, Artificial Neural Network, and Random Forest
CONCLUSION: In this study, it was shown that machine learning algorithms can be used with high accuracy to detect CAD. Thus, it allows physicians to perform timely preventive treatment in patients with CAD.PMID:37057235 | PMC:PMC10086656 | DOI:10.4103/abr.abr_383_21
Source: Adv Data - April 14, 2023 Category: Epidemiology Authors: Saeed Saeedbakhsh Mohammad Sattari Maryam Mohammadi Jamshid Najafian Farzaneh Mohammadi Source Type: research
Straight from the heart: Mysterious lipids may predict cardiac problems better than cholesterol
Stephanie Blendermann, 65, had good reason to worry about heart disease. Three of her sisters died in their 40s or early 50s from heart attacks, and her father needed surgery to bypass clogged arteries. She also suffered from an autoimmune disorder that results in chronic inflammation and boosts the odds of developing cardiovascular illnesses. “I have an interesting medical chart,” says Blendermann, a real estate agent in Prior Lake, Minnesota.
Yet Blendermann’s routine lab results weren’t alarming. At checkups, her low-density lipoprotein (LDL), or “bad,” cholesterol hovered around the 100 milligrams-per-...
Source: Science of Aging Knowledge Environment - March 16, 2023 Category: Geriatrics Source Type: research
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
A Sugar Replacement May Be Linked to Heart Attacks and Strokes. Don ’ t Throw Out Your Stash Yet
Sugar replacements are everywhere in foods and beverages. But despite their ubiquity, the scientific verdict on whether or not they pose health risks ping pongs back and forth. Every so often, though, a study is published with a conclusion so shocking that it forces people to reassess their pantries. A Feb. 27 study published in the journal Nature Medicine now seems to have dealt such a blow to the sweetener erythritol, with data that suggest a connection between the ingredient and cardiovascular events such as clotting, stroke, and heart attacks.
[time-brightcove not-tgx=”true”]
But before you clear your shel...
Source: TIME: Health - March 3, 2023 Category: Consumer Health News Authors: Haley Weiss Tags: Uncategorized Diet & Nutrition healthscienceclimate Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
